Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if ROIV is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
77 top institutions tracked
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: bearish
Last trade: sell 10 days ago
Red flags: 0
497 filers reported a long position in ROIV for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| FMR LLC | $2.9B | 81M | +3.9% |
| BlackRock, Inc. | $1.7B | 48.2M | +9% |
| MORGAN STANLEY | $1.5B | 42.6M | -17.8% |
| VANGUARD CAPITAL MANAGEMENT LLC | $782.9M | 22.1M | +7% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $765.9M | 21.6M | +9.1% |
| GOLDMAN SACHS GROUP INC | $656.7M | 18.6M | +67% |
| STATE STREET CORP | $629.8M | 17.8M | +9.9% |
| UBS Group AG | $618.1M | 17.5M | -22.8% |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $506.4M | 14.3M | +47.9% |
| GEODE CAPITAL MANAGEMENT, LLC | $425.5M | 11.7M | +14.7% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.